CoreFirst Bank & Trust’s Biogen BIIB Stock Holding History

CoreFirst Bank & Trust’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54.1K	Sell	295 -295	-50%	-$54.4K	0.03%	203
2025 Q4	$104K	Sell	590 -304	-34%	-$49.7K	0.06%	158
2025 Q3	$125K	Hold	894	–	–	0.07%	147
2025 Q2	$112K	Buy	+894	New	+$111K	0.06%	152
2025 Q1	–	Sell	-304	Closed	-$46.5K	–	136
2024 Q4	$46.5K	Hold	304	–	–	0.03%	222
2024 Q3	$58.9K	Buy	+304	New	+$63.6K	0.03%	207
2024 Q2	–	Sell	-304	Closed	-$65.6K	–	147
2024 Q1	$65.6K	Hold	304	–	–	0.04%	197
2023 Q4	$78.7K	Hold	304	–	–	0.05%	185
2023 Q3	$78.1K	Hold	304	–	–	0.06%	189
2023 Q2	$86.6K	Hold	304	–	–	0.06%	178
2023 Q1	$84.5K	Hold	304	–	–	0.06%	176
2022 Q4	$84.2K	Hold	304	–	–	0.06%	190
2022 Q3	$81K	Hold	304	–	–	0.07%	175
2022 Q2	$62K	Sell	304 -200	-40%	-$40.9K	0.05%	192
2022 Q1	$106K	Buy	504 +304	+152%	+$66.1K	0.07%	170
2021 Q4	$48K	Sell	200 -250	-56%	-$64.3K	0.03%	257
2021 Q3	$127K	Hold	450	–	–	0.09%	162
2021 Q2	$156K	Hold	450	–	–	0.11%	151
2021 Q1	$126K	Hold	450	–	–	0.09%	163
2020 Q4	$110K	Buy	+450	New	+$116K	0.08%	160

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CoreFirst Bank & Trust's BIIB Position: Q1 2026 in Review

CoreFirst Bank & Trust reduced its Biogen (BIIB) stake by 50% in Q1 2026, selling an estimated $54.4K and leaving 295 shares worth $54.1K. The position accounts for 0.03% of the portfolio, ranked #203.

CoreFirst Bank & Trust first reported a position in BIIB in Q4 2020 and has held it in 20 quarters since. The position peaked at $156K in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

CoreFirst Bank & Trust held 295 shares of Biogen worth $54.1K as of Q1 2026.
CoreFirst Bank & Trust sold 295 Biogen shares in Q1 2026, an estimated $54.4K.
Biogen made up 0.03% of CoreFirst Bank & Trust's portfolio in Q1 2026, its #203 holding.
CoreFirst Bank & Trust first reported a position in Biogen in Q4 2020 and has held it in 20 quarters since.
CoreFirst Bank & Trust's Biogen position peaked at $156K in Q2 2021.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2026, filed 3 Jun 2026.